Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DFN-15 Dose A · 1 trial · 1 indication
Percentage of subjects who are migraine headache free at 2 hours after taking study drug administration
| Arm | Type | Description |
|---|---|---|
| DFN-15 120 mg (treatment A) | EXPERIMENTAL | DFN-15 120 mg (treatment A) |
| DFN-15 240 mg (treatment B) | EXPERIMENTAL | DFN-15 240 mg (treatment B) |
| Placebo (treatment C) | PLACEBO_COMPARATOR | Placebo (treatment C) |
| Name | Type | Description |
|---|---|---|
| DFN-15 Dose A (treatment A) | DRUG | DFN-15 Dose A administered |
| DFN-15 Dose B (treatment B) | DRUG | DFN-15 Dose B administered |
| Placebo (treatment C) | OTHER | Placebo administered |
Inclusion Criteria: 1. Patients with a history of episodic migraine (as defined by International Classification of Headache Disorders \[ICHD\]-228) who experience an average of 2 to 6 migraine attacks a month for the past 12 months with no more than 14 headache days per month, and with at least 48 ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 13 | PHASE3 | Atogepant |
| Pfizer Inc. | PFE | 9 | PHASE3 | Rimegepant |
| Eli Lilly and Company | LLY | 2 | PHASE3 | Galcanezumab |
| Amgen Inc. | AMGN | 2 | PHASE3 | Erenumab Dose 1 |
| Ki Health Partners. LLC | RVNC | 1 | - | Daxibotulinumtonix A |
DFN-15 Dose A is an investigational small molecule being developed for the treatment of migraine. It is currently in Phase 2 clinical development, meaning it has not yet been approved by regulatory authorities and is still being studied for safety and efficacy in patients.
DFN-15 Dose A is being developed by Dr. Reddy's Laboratories Ltd, a pharmaceutical company listed on the stock exchange under the ticker RDY. The company is conducting clinical trials to evaluate the drug's potential in treating migraine.
DFN-15 Dose A is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to assess its safety and efficacy for the treatment of migraine.
DFN-15 Dose A has been studied in one completed Phase 2 clinical trial, identified as NCT02472418. This trial, titled 'Two Dose Levels of DFN-15 vs. Placebo in Patients With Migraine Headaches,' was a randomized, double-blind, placebo-controlled study conducted in the United States with 63 participants.
DFN-15 Dose A is a specific dose level of the investigational drug DFN-15. The clinical trial NCT02472418 evaluated two dose levels of DFN-15 against placebo in patients with migraine, and DFN-15 Dose A refers to one of those dose levels being tested.